TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07438886: A Non-Randomized, Open-Label Clinical Study of Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction (DDI) With Itraconazole and Ticagrelor in Healthy Volunteer Subjects

Sponsor: Advenchen Laboratories Nanjing Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,076,992

Rescue Site Savings

+$1,377,136

Unlock Full NCT07438886 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07438886 Rescue Dossier →